Retrospective case series shows complement inhibitors improve disability during acute NMOSD relapses, indicating potential for treatment.
This retrospective case series provides Class IV evidence that the C5 complement inhibitors eculizumab or ravulizumab may improve disability in patients with NMOSD when given during or shortly after acute relapse.
No takes yet. Share an insight, caveat, or question.
Rommer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: